{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T16:28:20Z","timestamp":1787502500221,"version":"build-2736575974"},"reference-count":98,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.clml.2025.07.013","type":"journal-article","created":{"date-parts":[[2025,7,27]],"date-time":"2025-07-27T14:11:26Z","timestamp":1753625486000},"page":"e976-e985","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Curing the Incurable: TP53 Mutated Myeloid Neoplasms"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7003-8798","authenticated-orcid":false,"given":"Nathan","family":"Punwani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saurabh","family":"Chhabra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.clml.2025.07.013_bib0001","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1038\/s41375-024-02417-1","article-title":"Managing the unmanageable: evidence-driven approaches to real-world patient prototypes of TP53-mutant myelodysplastic neoplasms and acute myeloid leukemia","volume":"38","author":"Patel","year":"2024","journal-title":"Leukemia"},{"issue":"17","key":"10.1016\/j.clml.2025.07.013_bib0002","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1001\/jama.2015.13134","article-title":"Potential mechanisms for cancer resistance in elephants and comparative cellular response to DNA damage in humans","volume":"314","author":"Abegglen","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.clml.2025.07.013_bib0003","article-title":"TP53 copy number expansion is associated with the evolution of increased body size and an enhanced DNA damage response in elephants","volume":"5","author":"Sulak","year":"2016","journal-title":"Elife"},{"issue":"9","key":"10.1016\/j.clml.2025.07.013_bib0004","doi-asserted-by":"crossref","first-page":"3606","DOI":"10.1093\/molbev\/msab127","article-title":"Elephant genomes reveal accelerated evolution in mechanisms underlying disease defenses","volume":"38","author":"Tollis","year":"2021","journal-title":"Mol Biol Evol"},{"issue":"1","key":"10.1016\/j.clml.2025.07.013_bib0005","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/s41420-023-01348-7","article-title":"Elephant TP53-RETROGENE 9 induces transcription-independent apoptosis at the mitochondria","volume":"9","author":"Preston","year":"2023","journal-title":"Cell Death Discov"},{"issue":"2","key":"10.1016\/j.clml.2025.07.013_bib0006","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.cell.2018.03.035","article-title":"Oncogenic signaling pathways in the cancer genome atlas","volume":"173","author":"Sanchez-Vega","year":"2018","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.clml.2025.07.013_bib0007","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/s41392-023-01347-1","article-title":"Targeting p53 pathways: mechanisms, structures, and advances in therapy","volume":"8","author":"Wang","year":"2023","journal-title":"Signal Transduct Target Ther"},{"issue":"6792","key":"10.1016\/j.clml.2025.07.013_bib0008","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/35018127","article-title":"PML regulates p53 acetylation and premature senescence induced by oncogenic Ras","volume":"406","author":"Pearson","year":"2000","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.clml.2025.07.013_bib0009","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1038\/ncb1448","article-title":"Plasminogen activator inhibitor-1 is a critical downstream target of p53 in the induction of replicative senescence","volume":"8","author":"Kortlever","year":"2006","journal-title":"Nat Cell Biol"},{"issue":"6","key":"10.1016\/j.clml.2025.07.013_bib0010","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1085\/jgp.8.6.519","article-title":"The metabolism of tumors in the body","volume":"8","author":"Warburg","year":"1927","journal-title":"J Gen Physiol"},{"issue":"7","key":"10.1016\/j.clml.2025.07.013_bib0011","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1158\/0008-5472.CAN-03-0846","article-title":"The tumor suppressor p53 down-regulates glucose transporters GLUT1 and GLUT4 gene expression","volume":"64","author":"Schwartzenberg-Bar-Yoseph","year":"2004","journal-title":"Cancer Res"},{"issue":"44","key":"10.1016\/j.clml.2025.07.013_bib0012","doi-asserted-by":"crossref","first-page":"E6806","DOI":"10.1073\/pnas.1607152113","article-title":"Activation of SAT1 engages polyamine metabolism with p53-mediated ferroptotic responses","volume":"113","author":"Ou","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"10.1016\/j.clml.2025.07.013_bib0013","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1158\/2159-8290.CD-18-1391","article-title":"A gain-of-function p53-mutant oncogene promotes cell fate plasticity and myeloid leukemia through the pluripotency factor FOXH1","volume":"9","author":"Loizou","year":"2019","journal-title":"Cancer Discov"},{"issue":"25","key":"10.1016\/j.clml.2025.07.013_bib0014","doi-asserted-by":"crossref","first-page":"3515","DOI":"10.1038\/onc.2016.518","article-title":"Mutant p53 oncogenic functions in cancer stem cells are regulated by WIP through YAP\/TAZ","volume":"36","author":"Escoll","year":"2017","journal-title":"Oncogene"},{"issue":"2","key":"10.1016\/j.clml.2025.07.013_bib0015","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.cell.2013.03.020","article-title":"Non-cell-autonomous tumor suppression by p53","volume":"153","author":"Lujambio","year":"2013","journal-title":"Cell"},{"issue":"12","key":"10.1016\/j.clml.2025.07.013_bib0016","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.1158\/2159-8290.CD-20-1741","article-title":"Pharmacologic activation of p53 triggers viral mimicry response thereby abolishing tumor immune evasion and promoting antitumor immunity","volume":"11","author":"Zhou","year":"2021","journal-title":"Cancer Discov"},{"issue":"12","key":"10.1016\/j.clml.2025.07.013_bib0017","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1158\/1078-0432.CCR-16-2554","article-title":"Potential predictive value of TP53 and KRAS mutation status for response to PD-1 blockade immunotherapy in lung adenocarcinoma","volume":"23","author":"Dong","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.clml.2025.07.013_bib0018","doi-asserted-by":"crossref","DOI":"10.1242\/jcs.237453","article-title":"H. p53, cancer and the immune response","volume":"133","author":"Blagih","year":"2020","journal-title":"J Cell Sci"},{"key":"10.1016\/j.clml.2025.07.013_bib0019","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1038\/ncomms3359","article-title":"53 increases MHC class I expression by upregulating the endoplasmic reticulum aminopeptidase ERAP1","volume":"4","author":"Wang","year":"2013","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.clml.2025.07.013_bib0020","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/leu.2008.173","article-title":"TP53 gene mutation is frequent in patients with acute myeloid leukemia and complex karyotype, and is associated with very poor prognosis","volume":"23","author":"Bowen","year":"2009","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.clml.2025.07.013_bib0021","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1002\/jha2.791","article-title":"Prognostic heterogeneity and clonal dynamics within distinct subgroups of myelodysplastic syndrome and acute myeloid leukemia with TP53 disruptions","volume":"4","author":"Patel","year":"2023","journal-title":"EJHaem"},{"issue":"14","key":"10.1016\/j.clml.2025.07.013_bib0022","doi-asserted-by":"crossref","first-page":"3348","DOI":"10.1080\/10428194.2021.1957869","article-title":"Clinico-genomic profiling and clonal dynamic modeling of TP53-aberrant myelodysplastic syndrome and acute myeloid leukemia","volume":"62","author":"Patel","year":"2021","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1016\/j.clml.2025.07.013_bib0023","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S1470-2045(16)30626-X","article-title":"Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study","volume":"18","author":"Takahashi","year":"2017","journal-title":"Lancet Oncol"},{"issue":"23","key":"10.1016\/j.clml.2025.07.013_bib0024","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.clml.2025.07.013_bib0025","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1053\/j.seminoncol.2008.04.007","article-title":"Cytogenetic, molecular genetic, and clinical characteristics of acute myeloid leukemia with a complex karyotype","volume":"35","author":"Mrozek","year":"2008","journal-title":"Semin Oncol"},{"issue":"15","key":"10.1016\/j.clml.2025.07.013_bib0026","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1182\/blood.2021014472","article-title":"Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome","volume":"139","author":"Grob","year":"2022","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.clml.2025.07.013_bib0027","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/nrc2723","article-title":"The first 30 years of p53: growing ever more complex","volume":"9","author":"Levine","year":"2009","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"10.1016\/j.clml.2025.07.013_bib0028","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/nrm2147","article-title":"p53 in health and disease","volume":"8","author":"Vousden","year":"2007","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.clml.2025.07.013_bib0029","doi-asserted-by":"crossref","DOI":"10.1200\/JCO-24-02394","article-title":"Characterization and clinical implications of p53 dysfunction in patients with myelodysplastic syndromes","author":"Zampini","year":"2025","journal-title":"J Clin Oncol"},{"issue":"24","key":"10.1016\/j.clml.2025.07.013_bib0030","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1182\/blood.2024024245","article-title":"TP53-mutated acute myeloid leukemia: how can we improve outcomes?","volume":"145","author":"Sallman","year":"2025","journal-title":"Blood"},{"issue":"6485","key":"10.1016\/j.clml.2025.07.013_bib0031","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1126\/science.aay9333","article-title":"The evolutionary dynamics and fitness landscape of clonal hematopoiesis","volume":"367","author":"Watson","year":"2020","journal-title":"Science"},{"issue":"6453","key":"10.1016\/j.clml.2025.07.013_bib0032","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1126\/science.aax3649","article-title":"A dominant-negative effect drives selection of TP53 missense mutations in myeloid malignancies","volume":"365","author":"Boettcher","year":"2019","journal-title":"Science"},{"issue":"13","key":"10.1016\/j.clml.2025.07.013_bib0033","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1101\/gad.1940710","article-title":"p53 loss promotes acute myeloid leukemia by enabling aberrant self-renewal","volume":"24","author":"Zhao","year":"2010","journal-title":"Genes Dev"},{"issue":"1","key":"10.1016\/j.clml.2025.07.013_bib0034","doi-asserted-by":"crossref","first-page":"5649","DOI":"10.1038\/s41467-019-13542-2","article-title":"Mutant p53 drives clonal hematopoiesis through modulating epigenetic pathway","volume":"10","author":"Chen","year":"2019","journal-title":"Nat Commun"},{"issue":"11","key":"10.1016\/j.clml.2025.07.013_bib0035","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1038\/s41588-020-00710-0","article-title":"Cancer therapy shapes the fitness landscape of clonal hematopoiesis","volume":"52","author":"Bolton","year":"2020","journal-title":"Nat Genet"},{"issue":"7540","key":"10.1016\/j.clml.2025.07.013_bib0036","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/nature13968","article-title":"Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia","volume":"518","author":"Wong","year":"2015","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.clml.2025.07.013_bib0037","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s41568-023-00658-3","article-title":"Translating p53-based therapies for cancer into the clinic","volume":"24","author":"Peuget","year":"2024","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"10.1016\/j.clml.2025.07.013_bib0038","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1182\/blood-2017-02-763086","article-title":"Dysfunctional diversity of p53 proteins in adult acute myeloid leukemia: projections on diagnostic workup and therapy","volume":"130","author":"Prokocimer","year":"2017","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.clml.2025.07.013_bib0039","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/s41573-022-00571-8","article-title":"Drugging p53 in cancer: one protein, many targets","volume":"22","author":"Hassin","year":"2023","journal-title":"Nat Rev Drug Discov"},{"issue":"11","key":"10.1016\/j.clml.2025.07.013_bib0040","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1016\/j.jmb.2017.03.030","article-title":"Mutant p53 in cancer: accumulation, gain-of-function, and therapy","volume":"429","author":"Yue","year":"2017","journal-title":"J Mol Biol"},{"issue":"1","key":"10.1016\/j.clml.2025.07.013_bib0041","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/s41408-024-01061-3","article-title":"Machine learning analysis of gene expression reveals TP53 mutant-like AML with wild type TP53 and poor prognosis","volume":"14","author":"Lee","year":"2024","journal-title":"Blood Cancer J"},{"issue":"6","key":"10.1016\/j.clml.2025.07.013_bib0042","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1158\/0008-5472.CAN-09-2661","article-title":"p53 Regulates the Ras circuit to inhibit the expression of a cancer-related gene signature by various molecular pathways","volume":"70","author":"Buganim","year":"2010","journal-title":"Cancer Res"},{"issue":"12","key":"10.1016\/j.clml.2025.07.013_bib0043","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1038\/nrd2759","article-title":"Double-edged swords as cancer therapeutics: simultaneously targeting p53 and NF-kappaB pathways","volume":"7","author":"Dey","year":"2008","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.clml.2025.07.013_bib0044","article-title":"Analysis of MDM2 amplification: next-generation sequencing of patients with diverse malignancies","volume":"2018","author":"Kato","year":"2018","journal-title":"JCO Precis Oncol"},{"issue":"2","key":"10.1016\/j.clml.2025.07.013_bib0045","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1182\/bloodadvances.2024014553","article-title":"T-cell immune cluster analysis using CyTOF identifies unique subgroups of patients with acute myeloid leukemia","volume":"9","author":"Badar","year":"2025","journal-title":"Blood Adv"},{"issue":"Suppl 4","key":"10.1016\/j.clml.2025.07.013_bib0046","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/ajh.27655","article-title":"TP53 -Mutated myeloid neoplasms: 2024 update on diagnosis, risk-stratification, and management","volume":"100","author":"Shah","year":"2025","journal-title":"Am J Hematol"},{"issue":"24","key":"10.1016\/j.clml.2025.07.013_bib0047","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1182\/blood.2020006158","article-title":"TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype","volume":"136","author":"Sallman","year":"2020","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.clml.2025.07.013_bib0048","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.clml.2025.07.013_bib0049","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1182\/bloodadvances.2024014140","article-title":"Diagnosis of TP53-mutated myeloid disease by the ICC and WHO fifth edition classifications","volume":"9","author":"Hart","year":"2025","journal-title":"Blood Adv"},{"issue":"6","key":"10.1016\/j.clml.2025.07.013_bib0050","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1093\/labmed\/lmae048","article-title":"TP53 mutations in myeloid neoplasms: implications for accurate laboratory detection, diagnosis, and treatment","volume":"55","author":"Zhang","year":"2024","journal-title":"Lab Med"},{"issue":"5","key":"10.1016\/j.clml.2025.07.013_bib0051","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/bjh.12203","article-title":"TP53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis","volume":"160","author":"Kulasekararaj","year":"2013","journal-title":"Br J Haematol"},{"issue":"16","key":"10.1016\/j.clml.2025.07.013_bib0052","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1182\/blood.2024023840","article-title":"Influence of TP53 gene mutations and their allelic status in myelodysplastic syndromes with isolated 5q deletion","volume":"144","author":"Montoro","year":"2024","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.clml.2025.07.013_bib0053","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1002\/cncr.34268","article-title":"Additional cytogenetic features determine outcome in patients allografted for TP53 mutant acute myeloid leukemia","volume":"128","author":"Loke","year":"2022","journal-title":"Cancer"},{"issue":"19","key":"10.1016\/j.clml.2025.07.013_bib0054","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.1182\/blood-2013-12-544957","article-title":"Outcome of patients with abnl(17p) acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation","volume":"123","author":"Middeke","year":"2014","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.clml.2025.07.013_bib0055","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1111\/bjh.13912","article-title":"TP53 mutation in patients with high-risk acute myeloid leukaemia treated with allogeneic haematopoietic stem cell transplantation","volume":"172","author":"Middeke","year":"2016","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.clml.2025.07.013_bib0056","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1002\/ajh.27647","volume":"100","author":"Esteve","year":"2025","journal-title":"Am J Hematol"},{"issue":"17","key":"10.1016\/j.clml.2025.07.013_bib0057","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1182\/blood-2016-12-754796","article-title":"Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation","volume":"129","author":"Yoshizato","year":"2017","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.clml.2025.07.013_bib0058","doi-asserted-by":"crossref","first-page":"5540","DOI":"10.1182\/bloodadvances.2023010312","article-title":"Interplay of TP53 allelic state, blast count, and complex karyotype on survival of patients with AML and MDS","volume":"7","author":"Stengel","year":"2023","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.clml.2025.07.013_bib0059","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1182\/bloodadvances.2019001101","article-title":"Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes","volume":"4","author":"Montalban-Bravo","year":"2020","journal-title":"Blood Adv"},{"issue":"10","key":"10.1016\/j.clml.2025.07.013_bib0060","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1038\/s41591-020-1008-z","article-title":"Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes","volume":"26","author":"Bernard","year":"2020","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.clml.2025.07.013_bib0061","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1182\/bloodadvances.2023010417","article-title":"Utility or futility? A contemporary approach to allogeneic hematopoietic cell transplantation for TP53-mutated MDS\/AML","volume":"8","author":"Nawas","year":"2024","journal-title":"Blood Adv"},{"issue":"28","key":"10.1016\/j.clml.2025.07.013_bib0062","doi-asserted-by":"crossref","first-page":"4497","DOI":"10.1200\/JCO.23.00866","article-title":"Allogeneic hematopoietic cell transplantation improves outcome in myelodysplastic syndrome across high-risk genetic subgroups: genetic analysis of the blood and marrow transplant Clinical Trials Network 1102 Study","volume":"41","author":"Versluis","year":"2023","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.clml.2025.07.013_bib0063","doi-asserted-by":"crossref","first-page":"3938","DOI":"10.1158\/1078-0432.CCR-08-2783","article-title":"Targeting DNA methylation","volume":"15","author":"Issa","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.clml.2025.07.013_bib0064","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.celrep.2017.06.067","article-title":"Integrative Genomics identifies the molecular basis of resistance to azacitidine therapy in myelodysplastic syndromes","volume":"20","author":"Unnikrishnan","year":"2017","journal-title":"Cell Rep"},{"issue":"21","key":"10.1016\/j.clml.2025.07.013_bib0065","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1056\/NEJMoa1605949","article-title":"TP53 and Decitabine in acute myeloid leukemia and myelodysplastic syndromes","volume":"375","author":"Welch","year":"2016","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.clml.2025.07.013_bib0066","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1016\/S2352-3026(18)30182-0","article-title":"Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial","volume":"6","author":"Short","year":"2019","journal-title":"Lancet Haematol"},{"issue":"4","key":"10.1016\/j.clml.2025.07.013_bib0067","doi-asserted-by":"crossref","first-page":"e177","DOI":"10.1016\/S2352-3026(19)30024-9","article-title":"10-day vs 5-day decitabine: equivalence cannot be concluded","volume":"6","author":"Huls","year":"2019","journal-title":"Lancet Haematol"},{"issue":"11","key":"10.1016\/j.clml.2025.07.013_bib0068","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1182\/blood.V81.11.3091.3091","article-title":"High expression of BCL-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy","volume":"81","author":"Campos","year":"1993","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.clml.2025.07.013_bib0069","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1158\/2159-8290.CD-13-0609","article-title":"Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia","volume":"4","author":"Pan","year":"2014","journal-title":"Cancer Discov"},{"issue":"7","key":"10.1016\/j.clml.2025.07.013_bib0070","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.clml.2025.07.013_bib0071","doi-asserted-by":"crossref","first-page":"5272","DOI":"10.1158\/1078-0432.CCR-22-1183","article-title":"Outcomes in patients with poor-risk cytogenetics with or without TP53 mutations treated with venetoclax and azacitidine","volume":"28","author":"Pollyea","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.clml.2025.07.013_bib0072","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41408-024-01000-2","article-title":"Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)","volume":"14","author":"Badar","year":"2024","journal-title":"Blood Cancer J"},{"issue":"20","key":"10.1016\/j.clml.2025.07.013_bib0073","doi-asserted-by":"crossref","first-page":"3772","DOI":"10.1002\/cncr.33689","article-title":"Outcomes of TP53-mutant acute myeloid leukemia with decitabine and venetoclax","volume":"127","author":"Kim","year":"2021","journal-title":"Cancer"},{"issue":"21","key":"10.1016\/j.clml.2025.07.013_bib0074","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1182\/blood.2024025409","article-title":"Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations","volume":"144","author":"Dohner","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.07.013_bib0075","doi-asserted-by":"crossref","DOI":"10.1038\/s41375-025-02668-6","article-title":"Chemoresistance of TP53 mutant acute myeloid leukemia requires the mevalonate byproduct, geranylgeranyl pyrophosphate, for induction of an adaptive stress response","author":"Skuli","year":"2025","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.clml.2025.07.013_bib0076","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13045-023-01417-5","article-title":"Treatment outcomes for newly diagnosed, treatment-naive TP53-mutated acute myeloid leukemia: a systematic review and meta-analysis","volume":"16","author":"Daver","year":"2023","journal-title":"J Hematol Oncol"},{"issue":"26","key":"10.1016\/j.clml.2025.07.013_bib0077","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1200\/JCO.2017.77.6112","article-title":"CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional Cytarabine plus Daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia","volume":"36","author":"Lancet","year":"2018","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clml.2025.07.013_bib0078","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1182\/bloodadvances.2020003159","article-title":"Real-life experience with CPX-351 and impact on the outcome of high-risk AML patients: a multicentric French cohort","volume":"5","author":"Chiche","year":"2021","journal-title":"Blood Adv"},{"issue":"16","key":"10.1016\/j.clml.2025.07.013_bib0079","doi-asserted-by":"crossref","first-page":"4539","DOI":"10.1182\/bloodadvances.2023010276","article-title":"A randomized comparison of CPX-351 and FLAG-Ida in adverse karyotype AML and high-risk MDS: the UK NCRI AML19 trial","volume":"7","author":"Othman","year":"2023","journal-title":"Blood Adv"},{"issue":"55","key":"10.1016\/j.clml.2025.07.013_bib0080","first-page":"144","article-title":"A randomized comparison of CPX-351 and FLAG-Ida in patients with high-risk acute myeloid leukemia (AML)\/Myelodysplastic syndrome (MDS) and MDS-related gene mutations: a subgroup analysis of the UK NCRI AML19 trial","author":"Mehta","year":"2024","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.clml.2025.07.013_bib0081","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1182\/blood.2024026700","article-title":"Venetoclax plus daunorubicin and cytarabine for newly diagnosed acute myeloid leukemia: results of a phase 1b study","volume":"145","author":"Mantzaris","year":"2025","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.clml.2025.07.013_bib0082","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1200\/JCO.20.03736","article-title":"Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed and relapsed or refractory acute myeloid leukemia","volume":"39","author":"DiNardo","year":"2021","journal-title":"J Clin Oncol"},{"issue":"56","key":"10.1016\/j.clml.2025.07.013_bib0083","article-title":"Phase II study of cladribine with low dose cytarabine and venetoclax alternating with azacytidine and venetoclax for newly diagnosed acute myeloid leukemia","volume":"144","author":"Bataller","year":"2024","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.clml.2025.07.013_bib0084","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1038\/s41418-024-01347-w","article-title":"Cell autonomous functions of CD47 in regulating cellular plasticity and metabolic plasticity","volume":"31","author":"Polara","year":"2024","journal-title":"Cell Death Differ"},{"issue":"8","key":"10.1016\/j.clml.2025.07.013_bib0085","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.1073\/pnas.1222861110","article-title":"Hematopoietic stem cell and progenitor cell mechanisms in myelodysplastic syndromes","volume":"110","author":"Pang","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"10.1016\/j.clml.2025.07.013_bib0086","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1182\/blood.2024027408","article-title":"Magrolimab plus azacitidine vs physician\u2019s choice for untreated TP53-mutated acute myeloid leukemia: the ENHANCE-2 study","volume":"146","author":"Zeidner","year":"2025","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.clml.2025.07.013_bib0087","first-page":"283","article-title":"Pathogenesis and inflammaging in myelodysplastic syndrome","volume":"110","author":"Villaume","year":"2025","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.clml.2025.07.013_bib0088","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/s13045-022-01385-2","article-title":"SIRPalpha-Fc fusion protein IMM01 exhibits dual anti-tumor activities by targeting CD47\/SIRPalpha signal pathway via blocking the ``don't eat me'' signal and activating the ``eat me'' signal","volume":"15","author":"Yu","year":"2022","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.clml.2025.07.013_bib0089","series-title":"Preliminary Results of a Phase 2 Study of IMM01 Combined With Azacitidine (AZA) as the First-Line Treatment in Adult Patients With Higher Risk Myelodysplastic Syndromes (MDS)","author":"Yang","year":"2023"},{"issue":"4","key":"10.1016\/j.clml.2025.07.013_bib0090","doi-asserted-by":"crossref","first-page":"e272","DOI":"10.1016\/S2352-3026(22)00403-3","article-title":"Eprenetapopt combined with venetoclax and azacitidine in TP53-mutated acute myeloid leukaemia: a phase 1, dose-finding and expansion study","volume":"10","author":"Garcia-Manero","year":"2023","journal-title":"Lancet Haematol"},{"issue":"14","key":"10.1016\/j.clml.2025.07.013_bib0091","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1200\/JCO.20.02342","article-title":"Eprenetapopt plus azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid leukemia: a phase II study by the Groupe Francophone des Myelodysplasies (GFM)","volume":"39","author":"Cluzeau","year":"2021","journal-title":"J Clin Oncol"},{"issue":"34","key":"10.1016\/j.clml.2025.07.013_bib0092","doi-asserted-by":"crossref","first-page":"3985","DOI":"10.1200\/JCO.22.00181","article-title":"Eprenetapopt plus azacitidine after allogeneic hematopoietic stem-cell transplantation for TP53-mutant acute myeloid leukemia and myelodysplastic syndromes","volume":"40","author":"Mishra","year":"2022","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/j.clml.2025.07.013_bib0093","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1182\/blood.2024025705","article-title":"How I treat AML relapse after allogeneic HSCT","volume":"145","author":"Gooptu","year":"2025","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.clml.2025.07.013_bib0094","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.ccell.2018.02.002","article-title":"ORY-1001, a potent and selective covalent KDM1A inhibitor, for the treatment of acute leukemia","volume":"33","author":"Maes","year":"2018","journal-title":"Cancer Cell"},{"issue":"7","key":"10.1016\/j.clml.2025.07.013_bib0095","doi-asserted-by":"crossref","first-page":"e487","DOI":"10.1016\/S2352-3026(24)00132-7","article-title":"Iadademstat in combination with azacitidine in patients with newly diagnosed acute myeloid leukaemia (ALICE): an open-label, phase 2a dose-finding study","volume":"11","author":"Salamero","year":"2024","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2025.07.013_bib0096","doi-asserted-by":"crossref","unstructured":"Daniel Nguyen, F. R., Sa A. Wang, et al. Updated results from a phase II study of vibecotamab, a CD3-CD123 bispecific T-cell engaging antibody, for MDS or CMML after hypomethylating failure and in MRD-positive AML. In 2024.","DOI":"10.1182\/blood-2024-208684"},{"issue":"20","key":"10.1016\/j.clml.2025.07.013_bib0097","doi-asserted-by":"crossref","first-page":"5011","DOI":"10.1182\/bloodadvances.2020002512","article-title":"TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML","volume":"4","author":"Vadakekolathu","year":"2020","journal-title":"Blood Adv"},{"issue":"11","key":"10.1016\/j.clml.2025.07.013_bib0098","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1182\/bloodadvances.2024014499","article-title":"TP53-mutant variant allele frequency and cytogenetics determine prognostic groups in MDS\/AML for transplantation","volume":"9","author":"Lontos","year":"2025","journal-title":"Blood Adv"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025002563?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025002563?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T03:39:04Z","timestamp":1776397144000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265025002563"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":98,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S2152265025002563"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2025.07.013","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Curing the Incurable: TP53 Mutated Myeloid Neoplasms","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2025.07.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}